Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland

This multicenter, retrospective cohort study evaluated the long-term safety and effectiveness of standardized European mistletoe extract (Viscum album L., Iscador) as an adjuvant to conventional oncologic therapy in 1,442 patients with primary non-metastasized breast cancer (UICC stage I–III). Over a median follow-up of 67 months, patients receiving mistletoe extract in